Cumberland Pharmaceuticals, Inc. (CPIX)
| Market Cap | 36.03M |
| Revenue (ttm) | 36.62M |
| Net Income (ttm) | -5.06M |
| Shares Out | 14.77M |
| EPS (ttm) | -0.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,702 |
| Open | 2.45 |
| Previous Close | 2.37 |
| Day's Range | 2.44 - 2.48 |
| 52-Week Range | 1.89 - 7.51 |
| Beta | 0.34 |
| Analysts | Sell |
| Price Target | n/a |
| Earnings Date | Aug 9, 2022 |
About CPIX
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatme... [Read more...]
Financial Performance
In 2021, CPIX's revenue was $35.99 million, a decrease of -3.89% compared to the previous year's $37.44 million. Losses were -$3.51 million, 5.04% more than in 2020.
Financial StatementsAnalyst Forecast
No stock price forecast available yet.
News
Cumberland Pharmaceuticals Reports 14% Revenue Growth
Expanding portfolio of FDA approved brands driving double digit growth NASHVILLE, Tenn. , Aug. 9, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company,...
CUMBERLAND PHARMACEUTICALS REPORTS 2.4M PATIENT DOSES DELIVERED, NO PRODUCT RECALLS, NO FDA ISSUES IN 2021
The company's annual sustainability report highlights its continued focus on and commitment to environmental, social and governance issues NASHVILLE, Tenn. , Aug. 8, 2022 /PRNewswire/ -- Cumberland Phar...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS
NASHVILLE, Tenn. , Aug. 2, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2022 financial...
CUMBERLAND PHARMACEUTICALS APPOINTS MARTIN BROWN JR. TO ITS BOARD OF DIRECTORS
NASHVILLE, Tenn. , July 19, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that Martin Brown Jr. has joined the company's Board ...
Cumberland Pharmaceuticals Reports 6% Revenue Growth
The Nashville-based specialty pharmaceutical company issues first quarter 2022 financial results and a company update NASHVILLE, Tenn. , May 10, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NA...
Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support for San...
Verity Pharmaceuticals will feature Sancuso across the U.S. through its established oncology commercial organization and customer network NASHVILLE, Tenn. , May 9, 2022 /PRNewswire/ -- Specialty pharma...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2022 FINANCIAL RESULTS
NASHVILLE, Tenn. , May 3, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the first quarter 2022 financial ...
TABUK AND CUMBERLAND PARTNER TO BRING INNOVATIVE ANTIBIOTIC WITH LIFE-SAVING POTENTIAL TO MIDDLE EAST
Vibativ ® treats patients with multidrug-resistant infections NASHVILLE, Tenn. and RIYADH, Saudi Arabia, March 31, 2022 /PRNewswire/ -- Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc...
CUMBERLAND PHARMACEUTICALS REPORTS 2021 FINANCIAL RESULTS & COMPANY UPDATE
NASHVILLE, Tenn., March 8, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company today announced full year 2021 financial results and provided a company...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2021 FINANCIAL RESULTS
NASHVILLE, Tenn., March 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release annual 2021 financial results an...
CUMBERLAND PHARMACEUTICALS ACQUIRES SANCUSO® FROM KYOWA KIRIN NORTH AMERICA
NASHVILLE, Tenn. and BEDMINSTER, N.J.
CPIX Stock Alert: Cumberland Pharma Doubles on FDA Approval News
Cumberland Pharmaceuticals stock is up more than 90% in morning trading after the FDA approved the expanded use of its pain medication. The post CPIX Stock Alert: Cumberland Pharma Doubles on FDA Approv...
Read Why Shares Of Nano Cap Cumberland Pharma More Than Doubled
The FDA has approved expanded labeling for Cumberland Pharmaceuticals Inc's (NASDAQ: CPIX) Caldolor, an intravenously delivered formulation of ibuprofen, to now include use in pre-operative administrati...
Caldolor® Now FDA Approved For Pre-Operative Administration
NASHVILLE, Tenn., Nov. 29, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has approve...
Cumberland Pharmaceuticals Reports Third Quarter 2021 Financial Results & Company Update
NASHVILLE, Tenn., Nov. 9, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and third quarter 2021 financial re...
Cumberland Pharmaceuticals To Announce Third Quarter 2021 Financial Results
NASHVILLE, Tenn., Nov. 2, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2021 financial results and provide a Company update after...
Cumberland Pharmaceuticals Launches RediTrex® Product Line For Active Rheumatoid, Juvenile Idiopathic And Severe Psor...
NASHVILLE, Tenn., Sept. 29, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today the national launch of its RediTrex ® (methotrexate) ...
Cumberland Pharmaceuticals (CPIX) Reports Break-Even Earnings for Q2
Cumberland (CPIX) delivered earnings and revenue surprises of 100.00% and 5.66%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Cumberland Pharmaceuticals Reports Second Quarter 2021 Financial Results & Company Update
NASHVILLE, Tenn., Aug. 10, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and second quarter 2021 financial ...
Earnings Preview: Cumberland
Cumberland (NASDAQ:CPIX) announces its next round of earnings this Tuesday, August 10. Here is Benzinga's everything-that-matters guide for this Tuesday's Q2 earnings announcement.
Earnings Preview: Cumberland Pharmaceuticals (CPIX) Q2 Earnings Expected to Decline
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cumberland Pharmaceuticals To Announce Second Quarter 2021 Financial Results
NASHVILLE, Tenn., Aug. 3, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2021 financial results and provide a Company update afte...
Cumberland Pharmaceuticals Reports 2.5M Patient Doses Delivered, No Product Recalls, No FDA Issues in 2020
NASHVILLE, Tenn., July 26, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today released its 2020 Sustainability Report, which details the compa...
John Rogers' Firm Makes Changes to Portfolio in June
John Rogers (Trades, Portfolio), leader of Ariel Investments, disclosed last week his firm made changes to its portfolio on June 30.
4 Small Drug Stocks Set to Escape the COVID-Led Industry Weakness
4 Small Drug Stocks Set to Escape the COVID-Led Industry Weakness